MARKET

ZYNE

ZYNE

Zynerba Pharmace
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.000
+0.041
+4.28%
Closed 19:37 05/23 EDT
OPEN
0.9700
PREV CLOSE
0.9590
HIGH
1.010
LOW
0.9500
VOLUME
112.64K
TURNOVER
--
52 WEEK HIGH
6.07
52 WEEK LOW
0.8361
MARKET CAP
43.60M
P/E (TTM)
-1.0616
1D
5D
1M
3M
1Y
5Y
Bullish Sentiment Across The Cannabis Space - Check Full Movers For May 23, 2022
GAINERS: RIV Capital (OTC:CNPOF) shares closed up 17.20% at $0.73
Benzinga · 18h ago
Cannabis Stock Gainers And Losers From May 19, 2022
GAINERS: Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares closed up 7.42% at $0.99
Benzinga · 4d ago
Marijuana Stock Movers For May 18, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 21.21% at $1.00
Benzinga · 5d ago
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
DEVON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando ...
GlobeNewswire · 05/17 11:00
Cannabis Stock Gainers And Losers From May 16, 2022
GAINERS: Sundial Growers (NASDAQ:SNDL) shares closed up 21.09% at $0.47
Benzinga · 05/16 20:49
Zynerba Pharmaceuticals R&D Expenses Reach $5.1M For Q1 2022, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million.
Benzinga · 05/16 13:24
BRIEF-Zynerba Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
reuters.com · 05/16 12:26
Recap: Zynerba Pharmaceuticals Q1 Earnings
  Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 11:55
More
No Data
Learn about the latest financial forecast of ZYNE. Analyze the recent business situations of Zynerba Pharmace through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZYNE stock price target is 6.60 with a high estimate of 9.00 and a low estimate of 1.000.
High9.00
Average6.60
Low1.000
Current 0.9400
EPS
Actual
Estimate
-0.21-0.16-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 119
Institutional Holdings: 13.54M
% Owned: 31.05%
Shares Outstanding: 43.60M
TypeInstitutionsShares
Increased
16
789.27K
New
12
108.04K
Decreased
18
710.24K
Sold Out
8
445.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.79%
Pharmaceuticals & Medical Research
-0.43%
Key Executives
Chairman/Chief Executive Officer/Director
Armando Anido
President
Terri Sebree
Chief Financial Officer/Vice President
James Fickenscher
Vice President - Business Development
Brian Rosenberger
Secretary
Albert Parker
Lead Director/Independent Director
Warren Cooper
Independent Director
John Butler
Independent Director
William Federici
Independent Director
Daniel Kisner
Independent Director
Kenneth Moch
Independent Director
Pamela Stephenson
No Data
No Data
About ZYNE
Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. The Company is focused on the development of pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and a heterogeneous group of rare epilepsies known as developmental and epileptic encephalopathies (DEE). Its lead product candidate, Zygel (ZYN002 CBD Gel) is a cannabidiol (CBD) gel for FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare epilepsies known as DEE. Its clinical program for Zygel includes clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS, ASD and 22q and the reduction of seizures and the treatment of associated symptoms in patients with DEE syndromes.

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.